| Efficacy and safety of topical nitric oxide− releasing berdazimer gel in patients with molluscum contagiosum: A phase 3 randomized clinical trial JC Browning, C Enloe, M Cartwright, A Hebert, AS Paller, D Hebert, ... JAMA dermatology 158 (8), 871-878, 2022 | 30 | 2022 |
| Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials SB Gasparyan, EK Kowalewski, F Folkvaljon, O Bengtsson, ... Journal of Biopharmaceutical Statistics 31 (6), 765-787, 2021 | 19 | 2021 |
| Application of Meta-analysis to evaluate relationships among ARIA-E rate, amyloid reduction rate, and clinical cognitive response in amyloid therapeutic clinical trials for … D Wang, EK Kowalewski, G Koch Therapeutic innovation & regulatory science 56 (3), 501-516, 2022 | 14 | 2022 |
| Design and analysis of studies based on hierarchical composite endpoints: insights from the DARE-19 trial SB Gasparyan, J Buenconsejo, EK Kowalewski, J Oscarsson, ... Therapeutic Innovation & Regulatory Science 56 (5), 785-794, 2022 | 12 | 2022 |
| Efficacy and safety of berdazimer 10.3%, a nitric oxide-releasing topical gel in patients with molluscum contagiosum: a phase 3 randomized clinical trial J Browning, C Enloe, MHA Cartwright, A Paller, D Hebert, E Kowalewski, ... JAMA Derm, 2022 | 6 | 2022 |
| Comments on “Sample size formula for a win ratio endpoint” by RX Yu and J. Ganju SB Gasparyan, EK Kowalewski, GG Koch Statistics in Medicine 41 (14), 2688-2690, 2022 | 5 | 2022 |
| Hierarchical Composite Endpoints in COVID-19: The DARE-19 Trial SB Gasparyan, EK Kowalewski, J Buenconsejo, GG Koch Case Studies in Innovative Clinical Trials, 95-148, 2023 | 2 | 2023 |
| Nasalis-based V to Y flap versus the bilobed flap K Flores, CA Degesys, E Kearney, P Retterbush, BG Merritt Dermatologic Surgery 47 (5), 618-622, 2021 | 2 | 2021 |
| Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis AS Paller, LJ Green, N Silverberg, S Stripling, M Cartwright, C Enloe, ... Pediatric Dermatology, 2024 | | 2024 |
| Methods to Address Control to Test Treatment Switching for Multi-Visit and Time-to-Event Clinical Trials EK Kowalewski The University of North Carolina at Chapel Hill, 2023 | | 2023 |
| Evaluation of a Method for Sample Size Reestimation for a Confirmatory Phase 3 Clinical Trial to Compare Two Test Treatments to Control EK Kowalewski, GG Koch Case Studies in Innovative Clinical Trials, 68-94, 0 | | |
